Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 31, Number 12—December 2025

Dispatch

West Nile Virus–Associated Hemophagocytic Lymphohistiocytosis, Switzerland

Clemente Lascano, Lena Groenendijk, Benjamin Bruno, Enrico Meduri, Ariane Malclès, Florian Laubscher, Francisco Javier Pérez-Rodriguez, Manuel Schibler, Christophe Marti, and Aude NguyenComments to Author 
Author affiliation: Geneva University Hospitals, Geneva, Switzerland (C. Lascano, L. Groenendijk, E. Meduri, A. Malclès, F. Laubscher, F.J. Pérez-Rodriguez, M. Schibler, C. Marti, A. Nguyen); Centre Hospitalier de Wallonie Picard, Tournai, Belgium (B. Bruno); University of Geneva, Geneva (A. Malclès, M. Schibler)

Main Article

Figure 1

Evolution of laboratory data for a patient with West Nile virus–associated hemophagocytic lymphohistiocytosis during hospitalization, Geneva, Switzerland. Results include C-reactive protein, ferritin, thrombocytes, leukocytes, and triglycerides. Pink shading indicates corticosteroid treatment.

Figure 1. Evolution of laboratory data for a patient with West Nile virus–associated hemophagocytic lymphohistiocytosis during hospitalization, Geneva, Switzerland. Results include C-reactive protein, ferritin, thrombocytes, leukocytes, and triglycerides. Pink shading indicates corticosteroid treatment.

Main Article

Page created: November 17, 2025
Page updated: January 01, 2026
Page reviewed: January 01, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external